Lenvatinib + Pembrolizumab in Select Solid Tumors ESMO 2016
October 13, 2016

Preliminary Results from Lenvatinib + Pembrolizumab Phase 1b Clinical Study in Select Solid Tumors Presented at ESMO 2016


Eisai Inc. announced the presentation of preliminary results of a Phase 1b clinical study (Study 111) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib (marketed in the U.S. under the brand name Lenvima®) in combination with the anti-PD-1 immunotherapy pembrolizumab (marketed under the brand name Keytruda®, developed by Merck & Co., Inc., known as MSD outside the U.S. and Canada) in patients with selected solid tumors at the European Society for Medical Oncology Congress.

“Eisai is committed to exploring the potential role that lenvatinib-based combinations may have for patients with difficult to treat cancers,” said Alton Kremer, MD, PhD, Chief Clinical Officer and Chief Medical Officer, Oncology Business Group, Eisai. “We are encouraged by these results and look forward to further exploring the combination of lenvatinib plus pembrolizumab in the next stage of clinical development.”